LEQSELVI

Serial Number 98567738
688

Registration Progress

Application Filed
May 24, 2024
Under Examination
Feb 25, 2025
Approved for Publication
Dec 31, 2024
Published for Opposition
Dec 31, 2024
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Aug 25, 2025 47 days

Basic Information

Serial Number
98567738
Deadline
August 25, 2025
Description
Statement of Use or 1st Extension Due
Filing Date
May 24, 2024
Published for Opposition
December 31, 2024
Drawing Code
3

Status Summary

Current Status
Active
Status Code
688
Status Date
Feb 25, 2025
Application
Pending
Classes
005

Rights Holder

Sun Pharmaceutical Industries, Inc.

03
Address
2 INDEPENDENCE WAY
Princeton, NJ 08540

Ownership History

Sun Pharmaceutical Industries, Inc.

Original Applicant
03
Princeton, NJ

Sun Pharmaceutical Industries, Inc.

Owner at Publication
03
Princeton, NJ

Legal Representation

Attorney
Craig Kuchii

USPTO Deadlines

Next Deadline
47 days remaining
NOA E-Mailed - SOU Required
Due Date
August 25, 2025
Extension Available
Until February 25, 2026

Application History

9 events
Date Code Type Description
Feb 25, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 31, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 31, 2024 PUBO A PUBLISHED FOR OPPOSITION
Dec 25, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 9, 2024 DOCK D ASSIGNED TO EXAMINER
Dec 9, 2024 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 2, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 2, 2024 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED
May 24, 2024 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of autoimmune, gastrointestinal, and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of skin disorders; pharmaceutical preparations for the treatment of hair loss disorders; pharmaceutical preparations, namely, medicated dermatological preparations; pharmaceutical preparations for the treatment of alopecia areata, atopic dermatitis, vitiligo, irritable bowel disease, ulcerative colitis, Crohn's disease and rheumatoid arthritis; none of the aforesaid being pharmaceuticals for the treatment of cardiovascular diseases

Additional Information

Design Mark
The mark consists of the word LEQSELVI in red, with stylized navy and yellow curved lines above the word.
Color Claim
The color(s) red, blue and yellow is/are claimed as a feature of the mark.

Classification

International Classes
005